Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769470 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery
A Phase 2 study of Breast Cancer, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 15
- Study locations
NCT00769470 is a Phase 2 study of Breast Cancer that has completed, run by Translational Oncology Research International. The registered enrollment target is 18 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 15 study locations across 5 states.
The verdict
NCT00769470, a Phase 2 study of Breast Cancer, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 15
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether docetaxel and carboplatin are more effective when given together with trastuzumab and/or lapatinib in treating women with stage I, stage II, or stage III breast cancer. PURPOSE: This randomized phase II trial is studying how well docetaxel and carboplatin work when given together with trastuzumab and/or lapatinib in treating women with stage I, stage II, or stage III breast cancer that can be removed by surgery.
Conditions Studied
Interventions
- DRUG carboplatin
- DRUG docetaxel
- BIOLOGICAL trastuzumab
- DRUG lapatinib ditosylate
Study Locations (15)
California
- Central Hematology Oncology Medical Group, Incorporated - Alhambra - Alhambra
- Comprehensive Blood and Cancer Center - Bakersfield
- St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center - Fullerton
- North Valley Hematology-Oncology Medical Group - Northridge
- Wilshire Oncology Medical Group, Incorporated - Pomona - Pomona
- Sansum Medical Clinic - Santa Barbara
- Central Coast Medical Oncology Corporation - Santa Maria
- Santa Barbara Hematology Oncology - Solvang - Solvang
- Cancer Care Associates Medical Group, Incorporated - Redondo Beach - Torrance
Florida
- Cancer Institute of Florida, PA - Orlando - Orlando
- Florida Hospital Cancer Institute - Orlando
- Hematology and Oncology Consultants, PA - Orlando - Orlando
Indiana
- Providence Medical Group - Haute Terre
Nevada
- Comprehensive Cancer Centers of Nevada - Henderson - Henderson
New Mexico
- New Mexico Cancer Center - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2009-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769470
The ClinicalTrials.gov registry entry for NCT00769470 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which carboplatin is the first listed.
NCT00769470 reports 15 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Indiana.
Frequently Asked Questions
What is clinical trial NCT00769470 about?
NCT00769470 is a clinical study titled "Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery". RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the abil...
What is the current status of trial NCT00769470?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2009-04.
What conditions does trial NCT00769470 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00769470?
The interventions under investigation include: carboplatin (DRUG), docetaxel (DRUG), trastuzumab (BIOLOGICAL), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00769470?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00769470 being conducted?
This trial has 15 study locations across California, Florida, Indiana, Nevada, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.